Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.9 Billion SEK | -2.68% |
| 2022 | 1.95 Billion SEK | 33.77% |
| 2021 | 1.45 Billion SEK | -3.09% |
| 2020 | 1.5 Billion SEK | 78.24% |
| 2019 | 845.2 Million SEK | 30.35% |
| 2018 | 648.41 Million SEK | 941.0% |
| 2017 | 62.28 Million SEK | 128.18% |
| 2016 | 27.29 Million SEK | -2.95% |
| 2015 | 28.12 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 1.68 Billion SEK | -11.17% |
| 2024 Q2 | 1.74 Billion SEK | 3.49% |
| 2023 FY | 1.9 Billion SEK | -2.68% |
| 2023 Q3 | 1.61 Billion SEK | -5.69% |
| 2023 Q2 | 1.7 Billion SEK | -4.45% |
| 2023 Q1 | 1.78 Billion SEK | -8.41% |
| 2023 Q4 | 1.9 Billion SEK | 17.91% |
| 2022 Q2 | 1.45 Billion SEK | 8.48% |
| 2022 FY | 1.95 Billion SEK | 33.77% |
| 2022 Q1 | 1.34 Billion SEK | -7.92% |
| 2022 Q3 | 1.51 Billion SEK | 4.1% |
| 2022 Q4 | 1.95 Billion SEK | 28.65% |
| 2021 Q1 | 1.38 Billion SEK | -7.95% |
| 2021 FY | 1.45 Billion SEK | -3.09% |
| 2021 Q4 | 1.45 Billion SEK | -17.46% |
| 2021 Q3 | 1.76 Billion SEK | 43.61% |
| 2021 Q2 | 1.23 Billion SEK | -11.19% |
| 2020 Q1 | 784.24 Million SEK | -7.21% |
| 2020 Q2 | 1.48 Billion SEK | 89.6% |
| 2020 FY | 1.5 Billion SEK | 78.24% |
| 2020 Q4 | 1.5 Billion SEK | 4.6% |
| 2020 Q3 | 1.44 Billion SEK | -3.14% |
| 2019 Q1 | 605.19 Million SEK | -6.67% |
| 2019 Q4 | 845.2 Million SEK | 0.52% |
| 2019 Q3 | 840.84 Million SEK | 19.02% |
| 2019 Q2 | 706.47 Million SEK | 16.73% |
| 2019 FY | 845.2 Million SEK | 30.35% |
| 2018 FY | 648.41 Million SEK | 941.0% |
| 2018 Q4 | 648.41 Million SEK | -5.73% |
| 2018 Q2 | 66.66 Million SEK | 16.89% |
| 2018 Q1 | 57.03 Million SEK | -8.44% |
| 2018 Q3 | 687.83 Million SEK | 931.78% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q4 | 62.28 Million SEK | 0.0% |
| 2017 FY | 62.28 Million SEK | 128.18% |
| 2016 FY | 27.29 Million SEK | -2.95% |
| 2015 FY | 28.12 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -1504.516% |
| Ziccum AB (publ) | 14.97 Million SEK | -12594.022% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -9383.304% |
| BioArctic AB (publ) | 1.18 Billion SEK | -60.238% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -2946.875% |
| Mendus AB (publ) | 755.95 Million SEK | -151.411% |
| Genovis AB (publ.) | 288.85 Million SEK | -557.955% |
| Intervacc AB (publ) | 259.61 Million SEK | -632.076% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -4429.538% |
| Active Biotech AB (publ) | 44 Million SEK | -4219.43% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -581.824% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -2957.905% |
| Aptahem AB (publ) | 63.02 Million SEK | -2915.551% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -282.984% |
| Kancera AB (publ) | 65.64 Million SEK | -2795.281% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -440.952% |
| Fluicell AB (publ) | 9.34 Million SEK | -20248.49% |
| Saniona AB (publ) | 64.14 Million SEK | -2862.987% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -5556.059% |
| Biovica International AB (publ) | 131.4 Million SEK | -1346.296% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -3486.957% |
| AcouSort AB (publ) | 34.51 Million SEK | -5406.763% |
| Xintela AB (publ) | 18.39 Million SEK | -10231.878% |
| Abliva AB (publ) | 87.49 Million SEK | -2072.081% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | -150.006% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | -51.03% |
| OncoZenge AB (publ) | 20.34 Million SEK | -9243.899% |
| Amniotics AB (publ) | 26.08 Million SEK | -7185.705% |
| 2cureX AB (publ) | 16.62 Million SEK | -11331.874% |
| CombiGene AB (publ) | 120.61 Million SEK | -1475.754% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -31174.461% |
| Camurus AB (publ) | 1.9 Billion SEK | 0.381% |
| Corline Biomedical AB | 100.1 Million SEK | -1798.556% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -973.023% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -1251.771% |
| I-Tech AB | 152.44 Million SEK | -1146.728% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | -86.687% |
| Cyxone AB (publ) | 43.65 Million SEK | -4253.565% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -2315.174% |
| Biosergen AB | 7.2 Million SEK | -26292.848% |
| Cantargia AB (publ) | 223.71 Million SEK | -749.552% |
| NextCell Pharma AB | 81.28 Million SEK | -2238.043% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | -148.352% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -6198.833% |
| Nanologica AB (publ) | 77.42 Million SEK | -2354.57% |
| SynAct Pharma AB | 228.01 Million SEK | -733.505% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -7001.405% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -8657.13% |
| LIDDS AB (publ) | 17.65 Million SEK | -10664.933% |
| Lipum AB (publ) | 12.11 Million SEK | -15594.046% |
| BioInvent International AB (publ) | 1.4 Billion SEK | -35.736% |
| Alzinova AB (publ) | 123.18 Million SEK | -1442.791% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -697.284% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -22378.403% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -2129.985% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -12681.956% |
| Simris Alg AB (publ) | 174.55 Million SEK | -988.815% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -775.676% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -190.823% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -2082.733% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -6566.722% |